Communiqués Red Light Holland Corp. OTC Markets

Actions

NFCPF

CA6651582000

Temps Différé OTC Markets			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-.--%	-

31/08	Rhelion Life Sciences Corp. publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI
07/08	Rhelion Life Sciences Corp. remplacera son symbole boursier TRIP par RHEL	CI

Communiqués

03/09	Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program	NE
31/08	Rhelion Life Sciences Reports First Quarter 2027 Results	NE
27/08	Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate	NE
25/08	Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression	NE
20/08	Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design	NE
19/08	Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO	NE
14/08	Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression	NE
14/08	RED LIGHT HOLLAND : Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson’s Disease Depression	PU
05/08	Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE	NE
29/07	Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences	NE
17/07	Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp	NE
16/07	Red Light Holland Announces New Filament Health PEX010 European Research Shipment	NE
08/07	Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg	NE
07/07	Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre	NE
18/06	Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health	NE
08/06	Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France	NE
04/06	Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers	NE
29/05	Red Light Holland : Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health’s GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate	PU
25/05	Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate	NE
14/05	Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research	NE
13/05	Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders	NE
12/05	Red Light Holland : Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions	PU
12/05	Red Light Holland : Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property	PU
08/05	Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property	NE
07/05	Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions	NE